ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 312 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,468,219 | -56.6% | 129,074 | -42.4% | 0.00% | -57.1% |
| Q2 2023 | $7,985,201 | +27.7% | 223,926 | -9.0% | 0.01% | +16.7% |
| Q1 2023 | $6,253,226 | -25.5% | 246,190 | +18.9% | 0.01% | -25.0% |
| Q4 2022 | $8,397,664 | -1.7% | 207,043 | -19.9% | 0.01% | -11.1% |
| Q3 2022 | $8,543,000 | -2.4% | 258,487 | +4.0% | 0.01% | 0.0% |
| Q2 2022 | $8,752,000 | -26.2% | 248,552 | -3.7% | 0.01% | -10.0% |
| Q1 2022 | $11,866,000 | -31.8% | 258,008 | -5.7% | 0.01% | -28.6% |
| Q4 2021 | $17,409,000 | +1.3% | 273,657 | -3.6% | 0.01% | -6.7% |
| Q3 2021 | $17,182,000 | -0.3% | 283,858 | +32.2% | 0.02% | 0.0% |
| Q2 2021 | $17,242,000 | +8.6% | 214,680 | -12.3% | 0.02% | 0.0% |
| Q1 2021 | $15,882,000 | +12.0% | 244,680 | +29.1% | 0.02% | 0.0% |
| Q4 2020 | $14,185,000 | +151.6% | 189,466 | +43.2% | 0.02% | +114.3% |
| Q3 2020 | $5,638,000 | +62.8% | 132,305 | +61.9% | 0.01% | +75.0% |
| Q2 2020 | $3,463,000 | – | 81,696 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,303 | $54,386,000 | 28.54% |
| JOHNSON & JOHNSON | 3,260,869 | $216,196,000 | 24.61% |
| ACT CAPITAL MANAGEMENT, LLC | 210,500 | $13,956,000 | 10.09% |
| Aquilo Capital Management, LLC | 700,426 | $46,438,000 | 5.27% |
| WEALTH EFFECTS LLC | 145,960 | $9,677,000 | 4.02% |
| Evolutionary Tree Capital Management, LLC | 115,580 | $7,663,000 | 3.68% |
| ACUTA CAPITAL PARTNERS, LLC | 105,500 | $6,995,000 | 2.94% |
| Privium Fund Management B.V. | 204,393 | $13,766,000 | 2.73% |
| L1 Capital Pty Ltd | 292,735 | $19,408,000 | 2.24% |
| Avidity Partners Management LP | 875,000 | $58,013,000 | 1.23% |